GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (STU:7AY1) » Definitions » Cyclically Adjusted Price-to-FCF

Actinium Pharmaceuticals (STU:7AY1) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Actinium Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Actinium Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Actinium Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Actinium Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Actinium Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Actinium Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Actinium Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinium Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


;
;

Actinium Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Actinium Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Actinium Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.225/134.9266*134.9266
=-0.225

Current CPI (Mar. 2025) = 134.9266.

Actinium Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -3.840 100.684 -5.146
201509 -2.273 100.392 -3.055
201512 -2.635 99.792 -3.563
201603 -2.913 100.470 -3.912
201606 -3.583 101.688 -4.754
201609 -3.126 101.861 -4.141
201612 -2.183 101.863 -2.892
201703 -2.702 102.862 -3.544
201706 -3.281 103.349 -4.283
201709 -2.039 104.136 -2.642
201712 -1.002 104.011 -1.300
201803 -1.504 105.290 -1.927
201806 -0.985 106.317 -1.250
201809 -1.553 106.507 -1.967
201812 -0.988 105.998 -1.258
201903 -1.255 107.251 -1.579
201906 -0.940 108.070 -1.174
201909 -0.934 108.329 -1.163
201912 -0.822 108.420 -1.023
202003 -0.914 108.902 -1.132
202006 -0.352 108.767 -0.437
202009 -0.275 109.815 -0.338
202012 -0.323 109.897 -0.397
202103 -0.258 111.754 -0.311
202106 -0.191 114.631 -0.225
202109 -0.223 115.734 -0.260
202112 -0.202 117.630 -0.232
202203 -0.237 121.301 -0.264
202206 1.102 125.017 1.189
202209 -0.232 125.227 -0.250
202212 -0.289 125.222 -0.311
202303 -0.551 127.348 -0.584
202306 -0.482 128.729 -0.505
202309 -0.386 129.860 -0.401
202312 -0.250 129.419 -0.261
202403 -0.244 131.776 -0.250
202406 -0.246 132.554 -0.250
202409 -0.347 133.029 -0.352
202412 -0.176 133.157 -0.178
202503 -0.225 134.927 -0.225

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Actinium Pharmaceuticals  (STU:7AY1) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Actinium Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinium Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Park Avenue, 23rd Floor, New York, NY, USA, 10017
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharmaceuticals Headlines

No Headlines